Myungmoon Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Myungmoon Pharm makes finished and active-ingredient medicines, the drugs themselves and the raw pharmaceutical compounds used to produce them, which it supplies to the domestic South Korean market and exports abroad.
It is listed on KOSPI, Korea's main stock exchange. The business operates in two segments: a pharmaceuticals and biotech division, which generates the large majority of revenue, and a services division covering golf-course and real-estate development. Its research pipeline includes generic medicines and improved reformulations of existing drugs, such as a treatment targeting high cholesterol.
Summary is AI-generated and may contain errors · figures from DART filings
The consolidated group includes a subsidiary, Myungmoon Bio, focused on pharmaceuticals, and a separate entity, Myungmoon Investment Development, running the non-pharma services business.
Myungmoon Pharm in five facts
What does Myungmoon Pharm do?
Myungmoon Pharm makes finished and active-ingredient medicines, the drugs themselves and the raw pharmaceutical compounds used to produce them, which it supplies to the domestic South Korean market and exports abroad.
Where is Myungmoon Pharm listed and in which sector?
Myungmoon Pharm (Korean name: 명문제약) trades under KRX code 017180 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Myungmoon Pharm?
Its market capitalisation was US$32.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Myungmoon Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Myungmoon Pharm reported revenue of US$147.4M, operating profit of US$5.2M and net income of US$1.1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 4.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 19
- Report on securities held by executives/major shareholdersOct 19
- Report on securities held by executives/major shareholdersOct 7
- Report on securities held by executives/major shareholdersOct 6
- Report on securities held by executives/major shareholdersSep 28
- Report on securities held by executives/major shareholdersSep 22
- Report on securities held by executives/major shareholdersSep 14
- Report on securities held by executives/major shareholdersSep 7
- Treasury share disposal: results reportTreasury Shares · Apr 29
- Material event report (treasury share disposal)
Myungmoon Pharm disclosed a plan to sell treasury shares worth US$633K, about 2.2% of its market value.
Treasury Shares · Apr 22 - Change of less than 30% in revenue or profit/loss structure (voluntary)
Myungmoon Pharm reported consolidated results for FY2025: revenue of US$134M (+4.7% year on year), operating profit of US$4.7M (+254.4% year on year) and net income of US$1.09M (from a loss a year earlier).
Earnings · Feb 11